Global Pediatric Vaccines Market was worth USD 32.59 Billion in 2020 and it is expected to reach USD 67.17 Billion by the end of 2027 with the CAGR of 7.5% during the Forecast Period.
Global Pediatric Vaccines Market: Global Size, Trends, Competitive, Historical & Forecast Analysis To 2021-2028,Rising awareness of pediatric vaccination, growing incidence of chronic disease in infants & children, and implementation of government and non-government organization in pediatric vaccination program are anticipated to drive the growth of Global pediatric vaccines market.
Vaccine is a preparation that are given in childhood to protect against serious diseases. Pediatric vaccines provide immunity to infants and children. Pediatric vaccines mainly consist of the dead microorganism, living fully virulent organism and attenuated organism that are stimulate to produce antibodies and provide immunity amongst the children. Pediatric vaccines prevent various diseases among infants & childrens such as polio, tetanus, influenza, diphtheria and many more. In 1963, measles vaccine was developed and vaccine was available to protect against mumps in 1967 and rubella in 1969. This three different vaccine was combined in 1971 to one single vaccine MMR by Dr. Maurice Hilleman.
COVID-19 pandemic has shown a positive impact on the global pediatric vaccines market, as the covid situation did not hampered the production of vaccination. Vaccinating infants and children will protect them against the diseases which will further reduce the risk of the hospitalization, risk of severe diseases and long term covid complications. According to WHO, around 84% of children received 1 dose and almost 70% of children received second dose of measles in 2020 and 83% of infant received polio vaccine around the world. Apart from the other restrictions due to lockdown the market showed the inclined graph globally.
Some major key players for global pediatric vaccines market report cover prominent players like
Global pediatric vaccines market is segmented on the basis of application, type, technology, and region and country level. Based on the application the global pediatric vaccines market is classified into influenza, measles & rubella, polio, hepatitis B, and others. Based on the type the global pediatric vaccines market is classified into multivalent vaccine and monovalent vaccine. Based on the technology, the global pediatric vaccines market is classified into subunits, inactivated virus, recombinant, conjugates and others.
One of the major factors driving the market growth is rising awareness of pediatric vaccination. Due to the vaccination, the rate of mortality and morbidity of infants & children has reduced tremendously. According to the UNICEF, child mortality rate declined by 59% under age 5 in the year 2019. According to the BMJ, child mortality rate declined from 12.6 million in 1990 to 6.3 million in 2013 including prevention of pneumonia, diarrhea and malaria, where the Global Vaccine Action Plan 2011–2020 worked. The effective vaccination worked for the tuberculosis, tetanus, and measles which helped in reducing infant and child mortality rates.
Another factor that drives the market is implementation of program through government & non-government initiatives. Global polio eradication was launched by the government in 1988. Almost 18 million people would have been paralyzed if initiative would not have been taken. Additionally, rising prevalence rate of chronic diseases in infants & children is another factor that drives the market. According to the CDC, 21,000 infants death was caused in United States due to sudden infant death syndrome in 2018. However, factors that restrain the market growth are low access of vaccine in rural & remote areas and high cost of the pediatric vaccine. For example, according to the CDC, the cost for the infanrix vaccine is 26 USD and the cost for the Pediarix vaccine is 63 USD. Additionally, opportunities in pediatric vaccines market will rise when players focus more on the research and development of the innovative & advanced vaccine in the upcoming years.
North America holds the largest market share owing to its well-established healthcare infrastructure, with increased awareness about vaccination. Increasing prevalence of chronic diseases in infants & children is the driving factor that boosts the pediatric vaccines market in North America region. Awareness towards vaccination, along with other preventative measures, to protect children from COVID-19 and other diseases using the safe, effective vaccines already recommended for use in adolescents and adults in the U.S. According to the CDC, the children of age 5-11 years will be vaccinated against covid 19 with BioNTech Pfizer pediatric vaccine where almost 28 million vaccines will be provided to children in U.S.
Asia Pacific holds the second largest market share in global pediatric vaccines market. Increasing immunization by government, key players are focusing more on developing pediatric vaccine are contributing to the global pediatric vaccine market. On the other hand government initiatives has increased the awareness and vaccination among large population. This initiative makes sure that maximum number of individual should be vaccinated with the low cost or no cost for the vaccination. For instance, Zydus Cadila’s ZyCoV-D vaccine which only cost nearly 265 Rs. According to the OECD, child vaccination is one of the most health policy program which prevent 3 million death per year which includes 86% of children are vaccinated and around 13 million children are never received vaccination. Another factor that drives the market is key players of this market that are mostly focusing on research & development in the vaccine. Apart from covaxin, these are the two vaccines of pediatric which is used as a ZyCoV-D has been tested on children above 12 years which is approved by USFDA manufactured by Zydus Cadila’s and Pfizer’s mRNA vaccine which is authorized to use on children.
The regions covered in this global pediatric vaccines market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, Southeast Asia, Middle East, GCC (UAE, Saudi Arabia, Kuwait), Africa, etc.
November 8th, 2021: Zydus Cadila is supplying 1 core dose of ZyCoV-D to government at the price of 265 Rs/ dose. An Indian approved dose of Zydus Cadila, ZyCoV-D which is the first plasmid DNA vaccine is a 3 dose shot mainly used for children of age 12 years and above. This vaccine can be used as the needle free applicators as an opposed to normal syringes. Zydus Cadila has also received the EUA, emergency used authorization from Drug controller general of India for ZyCoV-D. This vaccine will be used as a first priority for the children who are suffering from cancer, liver, cardiac, gastrointestinal, rheumatic disorders. This is the first vaccine in India for children. Being the DNA plasmid vaccine, for ZyCoV-D do not have any issue with vector based immunity. Zydus Cadila is the leading manufacturer in the pharmaceutical company that discovers and develops a very broad range of therapies.
|2015 - 2020
|2021 - 2027
|Market Size in 2020:
|USD 32.59 Billion
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2027:
|USD 67.17 Billion
|Tables, Charts & Figures:
|Pediatric vaccines Manufacturers
|GlaxoSmithKline plc., Sanofi SA, Panacea Biotech, Serum Institute of India, Pfizer Inc., Bharat Biotech, AstraZeneca plc., others
|By Type, By Application, By Technology
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®